Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a multicentric single arm phase II trial, to investigate the efficacy (in terms of
PFS) of the combination regimen rituximab-bendamustine in association with copanlisib in
patients affected by relapsed/refractory DLBCL, not eligible to HDC and ASCT or relapsed
after intensified regimens.